Agilent Technologies introduces industry’s most sensitive GC/MSD system
Pollutants and contaminants can now be detected at previously undetectable levels.
Agilent Technologies introduces the Agilent 5977B High Efficiency Source (HES) GC/MSD System, a tandem gas chromatograph and mass spectrometer that delivers lower limits of detection than any other instrument in its class.
“The 5977B is a major leap forward,” said Jim Yano, marketing vice president of Agilent’s Mass Spectrometry Division. “It includes a new high-efficiency ion source that makes it possible to detect pollutants and contaminants at previously undetectable levels.”
Agilent announced the breakthrough system at the Beijing Conference and Exposition on Instrumental Analysis, 27–30 October, an event the company has participated in since the conference began in 1985.
“The new system gives scientists the ability to detect trace levels of target compounds at levels 10 times lower than with any other single-quadrupole system,” Yano said. “Coupled with our MassHunter software, the 5977B is the most powerful GC/MSD ever.”
The Agilent 5977B will allow scientists to use smaller sample volume, spend less time on sample preparation, reduce instrument downtime, minimize solvent usage, and reduce the environmental impact of GC/MS analysis.
“Agilent supports scientists and researchers in their quest for answers and new discoveries through our technology, collaborations and insights,” said Patrick Kaltenbach, president of Agilent’s Life Sciences and Applied Markets Group. “Working closely with scientists in more than 100 countries, we deliver vital, actionable insights that advance our shared goal of creating a better world.”
In addition to the 5977B, Agilent is showcasing a wide range of solutions at the conference, including the following:
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance